



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
February 28, 2023**

Therapeutic Class	Drug Name	DURB Recommendation*
Hypoglycemics, Incretin Mimetics/Enhancers		
	<i>Mounjaro (Subcutaneous) Injection</i>	NP/PA
Sedative Hypnotics		
	<i>Quviviq (Oral) Tablet</i>	NP/PA
Antifungals, Oral		
	<i>Vivjoa (Oral) Capsule</i>	NP/PA
Antipsoriatics, Topical		
	<i>Vtama (Topical) Cream</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List